nuzefatide pevedotin (BT5528)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Pancreatic Ductal Adenocarcinoma (PDAC)

Drug Information

Target Indication

Pancreatic Ductal Adenocarcinoma (PDAC)

Clinical Trial

Last updated: 4/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BCYC

BICYCLE THERAPEUTICS PLC

Related Pipeline

Urinary Bladder Neoplasm

Metastatic Urothelial Cancer

Non-Small Cell Lung Cancer

Advanced Solid Tumor Historically Known for High EphA2 Expression

Advanced Solid Tumor

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts